Drug Trial Radar · NCT04716231
Atacicept in Subjects With IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
428
Actual
Start
Jun 29, 2023
Primary completion
May 15, 2025
Study completion Jul 2028
Sponsor
- Lead sponsor
- Vera Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Conditions
- IgA Nephropathy
- Berger Disease
Interventions
AtaciceptBiological
Once weekly subcutaneous (SC) injections by prefilled syringe
Placebo to match AtaciceptOther
Once weekly subcutaneous (SC) injections by prefilled syringe
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)Time frame: 36 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ORIGIN 3 Global Site Contact Information
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.